Welcome to our dedicated page for Vaxcyte SEC filings (Ticker: PCVX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Vaxcyte, Inc. filings document a clinical-stage vaccine company developing bacterial-disease vaccine candidates and raising capital through registered common stock transactions. Recent Form 8-K reports cover financial results, business updates tied to VAX-31 and other pipeline programs, an underwritten common stock offering, an at-the-market sales agreement under an effective Form S-3 shelf registration, and a manufacturing services agreement for drug product supply.
Proxy materials disclose shareholder voting matters, board and governance information, executive compensation, and equity-plan matters. The filing record also identifies Vaxcyte’s Nasdaq-listed common stock under PCVX and formalizes material agreements, financing arrangements, and corporate disclosures related to its vaccine development and manufacturing strategy.
Vaxcyte director Olivier Brandicourt received new equity awards consisting of restricted stock units (RSUs) and stock options. He was granted 2,194 RSUs, each representing one share of Vaxcyte common stock. These RSUs will fully vest on the earlier of June 15, 2027 or the day prior to the next annual stockholder meeting, subject to his continuous service.
He also received stock options for 11,034 shares of common stock at an exercise price of $49.56 per share, expiring on June 15, 2036. These options vest monthly and will be fully vested on the same earlier-of-2027-or-next-meeting schedule. Following the RSU grant, he directly holds 4,699 common shares.
Vaxcyte, Inc. director John Furey received equity awards as part of his compensation. He acquired 2,265 shares of Common Stock in the form of restricted stock units that will fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to his continuous service. Following this grant, he directly holds 5,306 shares of Common Stock.
Furey also received a stock option for 11,389 shares of Common Stock at an exercise price of $49.56 per share, expiring on June 15, 2036. These option shares vest monthly and will be fully vested on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to his continued service.
Vaxcyte, Inc. director Lee Jacks reported equity awards consisting of restricted stock units and stock options. He received 2,265 RSUs, each representing one share of common stock, and 11,389 stock options with an exercise price of $49.5600 per share.
The RSUs will fully vest on the earlier of June 15, 2027 or the day prior to the next annual stockholder meeting, subject to acceleration and his continuous service. The stock options vest monthly on the same overall schedule and expire on June 15, 2036. Following the grant, Jacks directly holds 6,856 shares of common stock, plus the newly granted options.
Vaxcyte, Inc. director Halley E. Gilbert received new equity awards from the company. He was granted 2,265 restricted stock units, each representing one share of common stock, which will fully vest on the earlier of June 15, 2027 or the day prior to the next annual stockholder meeting, subject to his continuous service.
He also received stock options for 11,389 shares of common stock at an exercise price of $49.56 per share, expiring on June 15, 2036. These options vest monthly and will be fully vested on the same earlier-of-2027-or-next-meeting schedule. Following the RSU grant, he directly holds 12,481 shares of common stock.
Vaxcyte, Inc. director Teri Loxam reported receiving equity-based compensation. The filing shows a grant of 2,265 shares of Common Stock underlying restricted stock units (RSUs) and a separate grant of stock options covering 11,389 shares of Common Stock.
The RSUs vest in full on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to continuous service, and delivery has been deferred under the company’s Nonqualified RSU Deferral Program for Non-Employee Directors. The stock options have an exercise price of $49.56 per share, vest monthly on the same schedule, and expire on June 15, 2036. Following the RSU grant, Loxam directly holds 12,481 shares of Common Stock.
Vaxcyte, Inc. director Anne S. Drapeau reported equity compensation awards rather than market trades. She received 2,265 shares of Common Stock in the form of restricted stock units, bringing her direct Common Stock holdings to 12,481 shares after the grant.
She was also granted a stock option for 11,389 shares of Common Stock at an exercise price of $49.56 per share, expiring on June 15, 2036. Both the RSUs and the option are scheduled to vest fully on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration and her continuous service.
Vaxcyte, Inc. director Heath Lukatch reported equity compensation awards rather than open-market trades. He received 2,265 shares of Common Stock through restricted stock units, with each RSU representing one share, and 11,389 stock options to buy Common Stock at an exercise price of $49.56 per share.
The RSUs will fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to continuous service and possible acceleration. The stock options vest monthly on the same schedule and expire on June 15, 2036. Following the RSU grant, Lukatch directly holds 19,481 shares of Common Stock.
Vaxcyte, Inc. held its Annual Meeting of Stockholders on June 15, 2026, where three Class III directors were re-elected to serve until the 2029 Annual Meeting. Olivier Brandicourt, M.D., Halley Gilbert, J.D., and Grant Pickering, M.B.A. each received strong shareholder support, with Brandicourt and Gilbert receiving over 114 million votes for and Pickering receiving over 132 million votes for, alongside broker non-votes.
Stockholders also ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, with more than 137 million votes in favor. In addition, shareholders approved, on a non-binding, advisory basis, the compensation of the company’s named executive officers, with approximately 130 million votes for, 2.8 million against, and additional abstentions and broker non-votes.
Vaxcyte, Inc. Chief Operating Officer Jim Wassil reported open-market sales of a total of 2,250 shares of common stock on June 1, 2026, at weighted-average prices around $50 per share. The transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 9, 2025.
After these sales, Wassil continues to hold about 158,000 shares of Vaxcyte common stock directly, indicating that the trades represent a small portion of his overall position and appear to be routine, pre-planned portfolio management rather than a change in fundamental outlook.
PCVX filed a Form 144 reporting proposed and recent dispositions of Common Stock by a holder. The filing lists RSU vesting events dated 08/31/2025 and 09/02/2025, and discloses three sales by James Wassil of 7,395, 2,250 and 2,250 shares on 03/10/2026, 04/01/2026 and 05/01/2026 respectively, with dollar values shown for each disposition.